ACESION PHARMA ApS: Financial statements 2015
CVR: 34083738
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
ACESION PHARMA ApS (CVR 34083738) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK -8,496,428 and a net result of DKK -9,804,270 compared with DKK -6,455,117 the year before. Equity in the 2015 report amounted to DKK 1,535,501. The solvency ratio was 8.9%.
- Gross Profit
- DKK -8,496,428
- Profit/Loss
- DKK -9,804,270
- Equity
- DKK 1,535,501
- Total Assets
- DKK 17,287,972
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | -8.5 mio. | -9.8 mio. | 1.5 mio. | - |
| 2014 | - | -4.7 mio. | -6.5 mio. | 3.8 mio. | - |
| 2013 | - | -4.8 mio. | -6.5 mio. | -556 t. | - |
| 2012 | - | -1.3 mio. | -2.1 mio. | 2 mio. | - |
Official annual report
How creditworthy is ACESION PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of August 15, 2015, Stephan Christgau has joined the board of directors of ACESION PHARMA ApS.
As of August 15, 2015, Bobby G Soni has left the board of directors of ACESION PHARMA ApS.
ACESION PHARMA ApS has published its annual report for 2014. Gross profit came to DKK -4,722,342, and the net result was DKK -6,455,117.
About ACESION PHARMA ApS
ACESION PHARMA ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2011. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Anders Gaarsdal Holst. The board consists of Jørgen Søberg Petersen (chair), Benjamin Bruno Thorner, Nik Economopoulos and Timothy Michael Shannon. The company's owners include Novo Holdings A/S, Canaan XII L.P. and Alpha Wave Ventures II, LP. The company has 14 employees (2018). In 2025, the company reported a net result of DKK -59,597,000 compared with DKK -43,033,000 the year before. Equity in the 2025 report amounted to DKK 276,067,000.